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ABSTRACT
Dietary consumption of genistein, found in soy, has been associated with a 
potentially protective role in colorectal cancer (CRC) development and progression. 
Herein we demonstrate that genistein will inhibit human CRC cell invasion and 
migration, that it does so at non-cytotoxic concentrations and we demonstrate 
this in multiple human CRC cell lines. After orthotopic implantation of human CRC 
tumors into mice, oral genistein did not inhibit tumor growth, but did inhibit distant 
metastasis formation, and was non-toxic to mice. Using a qPCR array, we screened for 
genistein-induced changes in gene expression, followed by Western blot confirmation, 
demonstrating that genistein downregulated matrix metalloproteinase 2 and Fms-
Related Tyrosine Kinase 4 (FLT4; vascular endothelial growth factor receptor 3). After 
demonstrating that genistein suppressed neo-angiogenesis in mouse tumors, we 
examined FLT4 expression in primary CRC and adjacent normal colonic tissue from 
60 human subjects, demonstrating that increased FLT4 significantly correlates with 
increased stage and decreased survival. In summary, we demonstrate for the first 
time that genistein inhibits human CRC metastasis at dietary, non-toxic, doses. FLT4 
is identified as a marker of metastatic disease, and as a response marker for small 
molecule therapeutics that inhibit CRC metastasis.
INTRODUCTION
Colorectal cancer (CRC) is the third leading cause 
of cancer-related death in developed countries [1]. 
Increased incidence of CRC has also been observed in 
developing countries, likely due to associated changes 
in diet and environment. The five-year survival rate 
exceeds 90% in patients diagnosed with early stage CRC, 
while it is less than 20% for those with metastatic CRC 
[2]. The development of metastasis is therefore a major 
determinant of survival. There are currently no treatments 
that selectively inhibit processes that drive metastasis. 
Thus, the discovery and development of a safe and 
effective drug that is able to inhibit human CRC metastasis 
remains an important goal. 
It is widely known that there is a wide variation 
in cancer rates from country to country. In particular, 
Asians, who have historically consumed a traditional 
diet high in soy, have a low incidence of clinical CRC 
[3]. However, Asians who immigrate to the United States 
and adopt a Western diet have an increased incidence of 
CRC [4]. These findings demonstrate that dietary and/
or lifestyle factors influence the incidence of CRC, and 
are consistent with the notion that soy consumption 
may be in part responsible. Further, there is a large 
body of epidemiologic evidence to suggest that diets 
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containing high amounts of soy are associated with an 
overall low rate of CRC mortality [5-7]. Genistein (4’, 5, 
7-trihydroxyisoflavone), which is present in high amounts 
in soy products, has been specifically evaluated in many 
of these studies, and is thought to represent a key bioactive 
component. It is reported that among the adult Chinese 
and Japanese populations, the average daily dietary intakes 
of genistein is 39 and 47 mg, respectively, whereas for 
those consuming a traditional Western diet, average daily 
consumption is only 1-2 mg/d [8-10]. As the incidence 
rate of CRC is historically much lower in Japan and China 
compared to Western countries, one possible explanation 
for this, at least in part, is that Asians consume much more 
genistein. 
Across a variety of experimental models, genistein 
has shown anticancer activity, typically in association 
with the suppression of cell proliferation and/or induction 
of apoptosis [11]. In CRC, previous studies have shown 
that genistein can decrease cell proliferation [12], and can 
induce G2/M phase cell cycle arrest and apoptosis [13]. 
Other studies implicate genistein’s role in carcinogenesis 
through the epigenetic modulation of DNA, including 
DNA promoter methylation and histone modification, 
resulting in altered miRNA expression patterns [14]. 
However, genistein’s effects are concentration dependent, 
the majority of these effects are observed in conjunction 
with high concentrations of genistein, i.e., mid-to-high 
micromolar concentrations, and the plethora of reported 
effects has raised concerns about specificity. At lower 
concentrations, overlapping with those achieved in the 
blood of humans after dietary consumption, genistein 
has been shown to inhibit cell motility and metastasis 
of human prostate cancer [15, 16]. However, the role of 
genistein in other cancers in this regard remains to be 
defined. We therefore conducted the current study designed 
to determine whether genistein affected human CRC 
metastasis. Further, given the complexity of metastasis and 
our current inability to successfully therapeutically target 
it [16], we sought to use genistein as a probe to analyze the 
associated underlying molecular mechanisms. 
Metastasis is a complex, multistep process made 
up of a cascade of sequential steps involving changes 
in cellular invasion, migration, adhesion, movement of 
cancer cells through the circulatory system, and their re-
implantation within a separate organ located at a distant 
site in the body, followed by colonization, tumor growth 
and the associated formation of new capillaries. In order 
to successfully metastasize, cancer cells must overcome 
what have been identified as three major barriers [17, 18]. 
The first relates to cellular attachment to the extracellular 
matrix, and the basement membrane in particular. Cells 
must re-program themselves in order to survive when 
not stably attached. The second requires an increased 
capacity to produce proteases that are able to induce local 
degradation of the extracellular matrix. And the third 
involves the ability of cancer cells to migrate through 
such a modified matrix. Increased cell migration, coupled 
to increased extracellular matrix degradation, constitute 
the major components of the composite process of 
cellular invasion. Increased cell invasion is an essential 
characteristic of the metastatic phenotype, is absolutely 
necessary for cells to successfully traverse the metastatic 
cascade, and strategies designed to selectively inhibit 
this process are actively being pursued, but remain 
elusive. The ability to inhibit initial cell invasion would 
in essence prevent the development of the series of events 
downstream from it that together lead to metastasis. 
Therefore, we began to investigate the effects of genistein 
on cell invasion and migration at cellular level, and then 
moved on to test CRC metastasis, using in vivo models.
In the current study, we demonstrate for the first time 
that genistein inhibits CRC cell invasive and migratory 
ability, and that it does so at concentrations that are not 
toxic to cancer cells in vitro. Using a clinically relevant 
orthotopic implantation murine model, we demonstrate 
that genistein inhibits human CRC cell metastasis. Based 
upon these positive findings, we went on to use genistein 
as a chemical probe to deepen our understanding of 
associated regulatory mechanisms. From an upfront 
screen, we went on to demonstrate that genistein 
suppresses expression of matrix metalloproteinase 2 
(MMP2) and of Fms-Related Tyrosine Kinase 4 (FLT4), 
and that it does so in cells in vitro and in tumor tissue in 
vivo. Focusing upon this newly identified role for FLT4, 
we demonstrate that its overexpression in human CRC 
tissue is associated with increased stage and early death 
from the development of metastatic CRC. We hereby 
identify genistein as an inhibitor of human CRC metastasis 
and an inhibitor of FLT4 expression. Further, we identify 
FLT4 as a potential marker for the development of 
metastatic CRC. 
RESULTS
Genistein’s effects on CRC cell viability 
As induction of cell death can falsely affect 
measurement of cell movement, our initial investigations 
sought to characterize the concentration of genistein 
that was not toxic to cells. We first performed a cell 
proliferation assay on HCT116, HT29 and SW620 
cells, treated with different concentrations of genistein, 
and measured effects upon cell growth each day, for 
five days. As shown in Fig. 1A, genistein inhibited cell 
growth in a concentration- and time-dependent manner. 
At 10 µmol/L, no significant effects were observed until 
after 72 hr, and then they were only minor. In contrast, 
at 25 and 50 µmol/L, genistein inhibited cell growth at 
48hr and decreased it by up to 83% at 5 days. We further 
corroborated these effects by performing colony formation 
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assays. After one day pre-treatment with different 
concentrations of genistein, cells were cultured for another 
10 days, and colonies counted. As depicted in Fig. 1B, 10 
µmol/L genistein did not decrease colony formation, while 
both 25 µmol/L and 50 µmol/L genistein significantly 
decreased colony formation in a concentration-dependent 
manner, and did so in all three cell lines tested. 
Genistein inhibits CRC cell invasion and 
migration 
For cell invasion and migration experiments, cells 
were treated with 10 µmol/L genistein for a total of 
48hr (24hr pre-treatment plus 24hr during invasion or 
migration). As indicated above, this concentration has no 
impact upon cell viability at 48hr, and even with continued 
treatment at 10 µmol/L, no effects are observed for another 
48 hr (i.e., at the 96 hr time point), and are even then 
only minor. Cell invasion was measured by a matrigel™ 
transwell invasion assay. As shown in Fig. 2A, genistein 
significantly inhibited cell invasion and cell migration in 
all three cell lines tested, inhibiting cell invasion by 36% 
to 56%, and inhibiting cell migration by 32% to 39%.
We further corroborated these findings in a wound 
healing assay and in the Cellomics high content cell 
migration system. The wound assay is shown in Fig. 
2B, and demonstrates that genistein significantly inhibits 
wound closure. With the Cellomics high content system, 
we tracked and quantified the movement of individual 
Figure 1: Genistein’s effects on CRC cell viability. (A) Effects of genistein on cell growth. HCT116, HT29 and SW620 cells were 
treated with 0, 10, 25 or 50 μmol/L genistein, and effects upon cell growth were measured daily over a five-day period. Data are the mean 
± SEM OD value from a single experiment run in replicates of N=3; similar results were observed in a separate experiment, also N=3. * 
denotes p<0.05 comparing the cell viability at the fifth day to control group (P, by student’s T TEST). (B) Effects of genistein on colony 
formation. One day after pretreatment at the indicated concentrations of genistein, cells were plated into 6-well plate at 1000 cells per well 
in the absence of genistein after 10 days, colonies counted. Data represented the mean ± SEM, from a single experiment run in replicates 
of N=3, and expressed as the percent of control (i.e., 0 µmol/L/vehicle only); similar results were observed in a separate experiment, also 
N=3. One-way ANOVA was used to calculate the significance of difference among groups. SNK analysis was used to compare differences 
between two groups as indicated in the figure. ns denotes p>0.05, * denotes p<0.05 compared to control group. 
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cells across a two dimensional surface over a 12-hr period 
of time. As can be seen in Fig. 2C, genistein significantly 
inhibited the migration of all three cell lines tested, with 
statistically significant effects detected as early as 180 
min. 
Genistein effects on distant organ metastasis in 
orthotopic nude mouse model
The above findings demonstrate that genistein 
can inhibit the migration and invasion of CRC cells 
at concentrations below which cell toxicity is seen. 
Given the central role of cell migration and invasion 
in driving metastasis, we hypothesized that genistein 
would inhibit human CRC metastasis. We tested this in 
an orthotopic implantation model of human CRC cells 
in mice. This model closely recapitulates human disease 
in that it requires cells to complete all of the steps in the 
metastatic cascades, including initial steps, such as neo-
angiogenesis formation, invasion out of the colon tract, 
as well as latter steps involving formation of distant 
metastasis. Specifically, in this experiment, small pieces 
of tissues from subcutaneous CRC tumors, arising from 
subcutaneously implanted cells, were transplanted into the 
cecal wall. Three days after orthotopic transplantation, 25 
Figure 2: Genistein inhibits CRC cell invasion and migration. (A) Transwell assay. Transwell assay was adopted to analyze cell 
invasion and migration of CRC cells. Cells on the lower side of the transwell membrane were counted. Representative images of different 
cell lines under different treatment conditions, stained with crystal violet and originally imaged at 200× magnification, are depicted. Data 
depicted graphically are the mean ± SEM of a single experiment, similar results were obtained in a separate experiment performed at a 
separate time, each experiment was in replicates of N=3. * denotes p<0.05 compared to vehicle control group by Student’s t test. (B) Wound 
healing assay. Cells were pretreated with 10 µmol/L genistein or vehicle for one day, the wound created, and wound closure over 48 hr 
was measured. The wound gap was calculated to reflect cell migration degree. The area of 0 hr was set as 100 percent, and the percent 
changes at 24-hr and 48-hr time point were recorded. Data represented the mean ± SEM of a single experiment, each in replicates of N=3. 
Similar results were obtained in a separate experiment performed at a separate time, also in replicates of N=3. * denotes p<0.05 compared 
to control group by student’s t test. (C) Cell migration assay. After pretreatment of cells with 10 μmol/L genistein for one day, average cell 
migration distance was recorded every 45 min over a 12-hr period of time as described in materials and methods. The data presented as 
one representative mean ± SEM from at least three separate experiments. * denotes P < 0.05 compared to control by student’s t test. GEN: 
genistein. 
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mg/kg/d or 75 mg/kg/d genistein or sesame oil (as control) 
was orally administered 5 days a week until the end of the 
experiment. After treatment for 5 weeks, primary tumor 
size and metastases were measured. Metastases were 
quantified by measuring bioluminescence in whole lung 
and liver organs immediately after necropsy (Fig. 3A). 
As can be seen in Figs. 3B and C, genistein 
significantly inhibited metastasis to both lung and liver 
in a dose-dependent manner (ANOVA p < 0.001). With 
lung, metastases were significantly lower in 25 and 75 
mg/kg/d groups, as compared to control (SNK p < 0.05, 
respectively). However, the difference between 25 and 75 
mg/kg/d groups was not significant (SNK p = 0.226). With 
liver, metastases were also significantly lower in 25 and 75 
mg/kg/d groups, as compared to control (SNK p < 0.05, 
respectively), and metastases in the 75 mg group were 
significantly lower than those of the 25 mg group (p < 
0.05). We did not find ascites in any of our mice, although 
it was reported in other studies that ascites appeared after 
orthotopic tumor implantation [19, 20]. The existence of 
primary tumors and metastatic loci in lung and liver were 
confirmed by H&E staining (Fig. 3D). We also measured 
primary tumor weight and size for each mouse. As shown 
in Figs. 3E and F, genistein treated groups showed a 
tendency toward reduced tumor weight (ANOVA p value 
= 0.276) and tumor size (ANOVA p value = 0.354), but 
the difference was not significant. Together, these findings 
demonstrate that genistein inhibits human CRC metastasis 
in a dose-dependent manner. 
Our previous study with genistein on mice using 
doses at and above current doses, comprehensively 
evaluated the systemic side effects of genistein in mice, 
failed to find any toxicity [21]. For the current study, 
we therefore only measured body weight, in addition to 
observing animal behavior. Genistein had no effect upon 
behavior, nor upon body weight (Fig. 3G). These findings 
indicate that genistein did not exert systemic toxicity in 
mice at the given doses. 
It is recognized that the propensity to metastasize 
increases as tumor mass increases. As we found a tendency 
for reduced tumor weight by genistein, this raises the 
possibility that the differences in metastasis observed in 
the current study might just result from differences in 
tumor mass. If this were the case, then tumor mass should 
closely correlate with degree of metastasis. We went on 
to demonstrate that there was a poor correlation between 
tumor mass and metastasis at the individual mouse level 
(Fig 3H, I). A weak positive correlation trend was noticed 
between tumor weight and lung metastasis (Pearson 
R=0.322, 95% CI: 0.020 to 0.570 P=0.038, R2=0.104), 
whereas the result for liver was not significant (Pearson 
R=0.119, 95% CI: -0.192 to 0.408 P=0.455, R2=0.014). 
These findings indicate that the anti-metastatic effect of 
genistein results from factors other than primary tumor 
growth. 
Genistein’s effects on angiogenesis and cell 
proliferation in vivo
We next examined expression in orthotopic tumor 
tissues of the cell proliferation marker, Ki67, and the 
angiogenesis marker, CD34, by immunohistochemistry. 
Our results showed that although the percentage of Ki67 
positive tumor cells showed a decreased trend after 
genistein treatments, the decreases were not statistically 
significant (one-way ANOVA p value =0.126) (Fig. 
4, upper panel). This was in agreement with our above 
findings that no significant effect upon tumor weight was 
observed. Further, both of these findings are consistent 
with our in vitro results, which demonstrate the ability to 
achieve anti-motility effects in the absence of cell toxicity. 
However, genistein did significantly reduce microvessel 
density, as reflected by decreased CD34 staining in tumor 
tissues, and it did so in a dose-dependent manner, with 
the strongest reduction observed in the 75 mg/kg/d group 
(p=<0.000) (Fig. 4, lower panel). 
Identification of metastasis-related genes affected 
by genistein
Having demonstrated genistein’s ability to inhibit 
human CRC metastasis, we next sought to use it as 
a chemical probe to better understand the molecular 
regulation of CRC metastasis. We approached this by 
treating HCT116 cells with/without 50 μmol/L genistein 
for 1day, followed by screening for altered gene 
expression on an 84-gene human tumor metastasis PCR 
array platform. Genes with more than twofold changes 
were considered of interest. Based upon this, 8 out of the 
84 genes were downregulated, while 4 were upregulated 
(Table S1). We then tested these 14 genes by qPCR and 
confirmed MMP2 and FLT4 RNA levels were decreased 
by genistein (Fig. 5A). Next, we examined the effect 
of genistein on MMP2 and FLT4 protein expression in 
HCT116, HT29, and SW620 cells by Western blot (Fig. 
5B). In all three cell lines tested, genistein decreased the 
expression of both MMP2 and FLT4 proteins. To check if 
this was the case in vivo, we measured protein expression 
in tissue sections from tumors of genistein treated or 
control mice by immunohistochemistry. As seen from 
Figs. 5C and D, genistein significantly decreased both 
MMP2 and FLT4 expression in a dose-dependent manner. 
Taken together, these findings demonstrate that genistein 
selectively suppresses MMP2 and FLT4 expression, and 
that it does so both in vitro and in vivo.
Prognostic role of FLT4 in human CRC 
The above findings demonstrate that genistein 
decreases MMP-2 and FLT4 expression coincident 
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Figure 3: Genistein effects on distant organ metastasis in orthotopic nude mouse model. Cohorts of 14 mice were 
orthotopically implanted with CRC cells. Images from luminescent imaging by IVIS system at the end of experiment were taken. The 
photon counts were automatically calculated by the software installed with the instrument. All exposure time and imaging parameters 
were set equally to generate comparable results. (A) Representative bioluminescent images from first batch of study with 6 nude mice in 
each cohort were presented. Left, whole mouse, upper right, lung, lower right, liver. The color scale depicts the photon flux (p/s) emitted. 
(One mouse in the control group died before the end of experiment.) (B, C) Imaging results of whole lung (B) and liver (C) organs were 
transformed to scatter plot scheme and the horizontal bar represented median value of each group. The Y axis was formalized as Log10 
scale. Data from two batches studies, including total 14 mice in each group were presented. One-way ANOVA was used to calculate the 
significance of difference among groups. SNK analysis was used to compare differences between each two groups. ns denotes p>0.05. * 
denotes p<0.05 (D) Representative H&E staining of tissues from mice were displayed to show orthotopic tumor and metastatic loci in lung 
and liver. (E, F) Primary tumors formed by orthotopic implantation were separated and the weight (E) and volume (F) from each tumor were 
measured. Tumor volume was calculated as 0.52× (width) 2× (length). The mean ± SEM value from each cohort (sesame oil, 25 mg/kg/d 
genistein and 75 mg/kg/d) was presented as bar chart. One-way ANOVA was used to calculate the significance of difference among groups 
SNK analysis was used to calculate significance of differences between each two groups. ns denotes p>0.05. (G) Mice weight was recorded 
every week after surgery. The mean ± SEM value of each cohort was presented. (P>0.05 by one-way ANOVA). (H, I) Correlation between 
tumor weight and distant organ metastasis was showed. The graph depicts the metastatic image signal at lung (H) or liver (I) plotted against 
the tumor weight for each mouse. The Pearson R between these two parameters was determined. GEN: genistein. 
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with inhibition of CRC metastasis. MMP-2 has a well-
established role in regulating cancer cell invasion and 
metastasis, in a variety of cancer types (32, 33), including 
CRC. Thus, while of clear importance to cancer, and 
to invasion and metastasis in particular, its role in this 
regard is relatively ubiquitous. Further, its function as an 
extracellular proteinase has been particularly difficult to 
therapeutically target with any type of selective efficacy. 
In contrast, FLT4 is an intracellular kinase, and little is 
known about its role in regulating metastasis, and CRC 
metastasis in particular. We therefore focused further 
investigations on FLT4. We utilized a colon human 
tissue array to examine the relationship between FLT4 
expression and clinicopathological characteristics. This 
array included 60 cases of colon cancer tissues and normal 
colon mucosal tissues from the same patient diagnosed 
Figure 4: Genistein’s effects on angiogenesis and cell proliferation in vivo. Representative images of Ki67 and CD34 IHC 
staining from each cohort were displayed. The percentage of Ki67 in each specimen was calculated and the microvessel density was 
determined by the average number of positive CD34 staining in five random selected 200× fields. Data represent mean ± SEM for all 
mice in a given cohort. Scale bar: 50 μm. One-way ANOVA was used to calculate the significance of difference among groups. For CD34 
staining, Games-Howell analysis was used to compare differences between two groups. For Ki67 staining, SNK analysis was used to 
compare differences between two groups. * denotes p<0.05 compared to controls. ns denotes p>0.05 compared to controls. GEN: genistein. 
Table 1: Clinic pathological association of FLT4 in colon cancer 
Characteristic Number of specimens
FLT4 expression P value0 1 2 3
Gender 0.498
Male 31 3 12 7 9





I 5 2 3 0 0
II 31 5 13 6 7
III 22 2 3 9 8
IV 2 0 0 0 2
Lymph node 
metastases 0.013
0 36 7 16 6 7
≥1 24 2 3 9 10
χ2 test was used to analyze the relationship of FLT4 expression and clinicopathological 
factor.  P values less than 0.05 were considered significant.
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Figure 5: Identification of metastasis-related genes affected by genistein. (A) The mRNA level of FLT4 and MMP2 was 
evaluated by qRT/PCR in HCT116 cells after genistein/DMSO treatment. Data represented the mean ± SEM of a single experiments, each 
in replicates of N=3. Similar results, normalized to 18S respectively, was assessed in at least 2 independent experiments, each in replicates 
of N=3. All control values were normalized to 1.0. * denotes p<0.05 compared to controls. (B) Protein level of FLT4 and MMP2 was 
measured by western blot in HCT116, HT29 and SW620 cells and β-actin served as the internal control. Depicted blots are representative, 
with similar results seen at least in one separate experiment. (C) MMP2 and FLT4 levels were studied in tumor tissue sections acquired 
from in vivo study by IHC staining and the representative images of IHC staining from each cohort were shown. Scale bar: 50 μm. (D) The 
expression level of MMP2 (left panel) and FLT4 (right panel) in tumor tissue sections was evaluated according to the scoring procedures 
described in materials and methods. Results were presented as a percentage ratio with the control group set as 100%. One-way ANOVA was 
used to calculate the significance of difference among groups, SNK analysis was used to calculate significance of differences between each 
two groups. * denotes p<0.05 compared with control group. ns denotes p>0.05 compared with controls. GEN: genistein. 
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with colon adenocarcinoma. In this manner, we found that 
FLT4 expression level was significantly increased in CRC 
compared to that in paired non-cancerous tissues (Table 
S2). Furthermore, increased FLT4 was found to correlate 
with advanced clinical stage and with the presence of 
lymph node metastasis, but not with gender and age (Table 
1, Fig. 6A). We then went on to analyze the relationship 
between FLT4 expression and patient prognosis by the 
Kaplan-Meier method (Fig. 6B). Patients with higher 
FLT4 expression had a statistically significant worse 
prognosis. Specifically, among 60 patients examined, 
those exhibiting weak, moderate and strong staining had a 
median survival of 76, 49 and 21 months respectively (p 
value =0.001). These results demonstrate that increased 
FLT4 is a poor prognostic marker for CRC, and implicate 
it in CRC progression. 
DISCUSSION
We demonstrate for the first time that genistein can 
inhibit the invasion, migration and metastasis of CRC 
cells. Further, we accomplished this with human CRC 
cells. Importantly, we demonstrate this function in vitro 
at concentrations that are non-toxic to cells. The non-
toxic nature of therapy in association with therapeutic 
efficacy is further supported by findings in our systemic 
murine models. Specifically, we observed anti-metastatic 
efficacy in a dose-responsive fashion, while observing 
no evidence of systemic toxicity. Further, genistein did 
not significantly inhibit tumor growth, nor did it inhibit 
cell growth, as assessed by Ki67 expression. These in 
vivo findings directly support our in vitro ones, which 
demonstrate that anti-motility effects can be induced at 
concentrations that do not induce toxic effects. Finally, we 
further corroborated the specificity of in vivo findings by 
going on to demonstrate that there was a poor correlation 
between tumor size and number of metastasis. 
It is also of importance to note that anti-
motility efficacy is observed in vitro at concentrations 
that approximate those attainable in the blood with 
Figure 6: Prognostic role of FLT4 in human CRC. (A) Representative images of normal colon tissue with negative staining (left), 
cancer tissue with medium (middle) or strong staining (right) were displayed. Scale bar: 50 μm. (B) Kaplan-Meyer method was used to 
analyze relationship between FLT4 expression and patients’ prognosis. Increased expression of FLT4 indicated worse overall survival 
(P=0.001).
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administration of dietary doses to humans. Further, we 
demonstrate anti-metastatic efficacy in a murine model in 
which genistein is delivered via the oral route, as it would 
be through dietary consumption. Finally, we know from 
prior work by us that the doses we administered to mice 
provide blood concentrations that directly overlap with 
those attained by dietary consumption [22-24]. The clinical 
relevance of our findings is further supported by the fact 
that efficacy was observed at genistein dosages taken daily 
with Eastern-style diet or Western-style diet supplemented 
with genistein [10, 24]. As our further analysis of 
primary tumor weight with the occurrence of lung or 
liver metastasis did not reveal their close correlation, 
our findings indicate that inhibition of CRC metastasis 
by genistein is not dependent on primary tumor growth. 
Together, these findings provide a mechanistic explanation 
for the lower incidence of clinical, i.e., metastatic, CRC 
observed in high soy consuming populations. Based upon 
these findings, it will be important to begin evaluating this 
potential mechanism in humans, and to compare findings 
in cohorts who consume high soy versus those who do not. 
Also, having demonstrated genistein’s therapeutic 
efficacy, this led us to use genistein as a chemical probe. 
These studies were successful in that we found that 
genistein decreased expression of MMP-2 and FLT4. The 
finding that genistein decreased MMP-2 expression served 
as an important positive control for these studies. This is 
because MMP-2 has been widely implicated in cancer cell 
invasion and metastasis in a wide array of cancer types, 
including CRC (32, 33). Further, genistein has been shown 
to decrease MMP-2 expression in human prostate cancer, 
coincident with its ability to inhibit human prostate cancer 
cell invasion [25, 26]. 
Our identification that genistein decreased FLT4 
expression was considered of particularly high potential 
importance by us. FLT4 is also known as vascular 
endothelial growth factor receptor 3 (VEGFR3), and it has 
been implicated in cancer related to its role in increasing 
neo-angiogenesis [27]. Previous work on the receptor has 
produced variable findings, with some studies identifying 
its expression in tumors but failing to find any correlation 
between level of expression and clinicopathological 
parameters [28], whilst several studies do report a 
positive and significant correlation between the level of 
FLT4 expression in the tumor and the development of 
metastasis and poor prognosis [29, 30]. Our results point 
to a significant positive correlation between increased 
FLT4 expression and an aggressive tumor phenotype and 
resultant poor survival. Specifically, we demonstrated that 
elevated FLT4 was associated with lymph-node metastasis, 
advanced stage, and with early death from CRC. Our 
findings are in agreement with those drawn from the 
studies of others involving a larger sample analysis [29, 
30]. Furthermore, our findings are in agreement with the 
current biological role of the VEGF family of receptors, 
inclusive of FLT4, as drivers of neo-angiogenesis, and 
resultant metastasis. Our identification of FLT4 as an 
important regulator of cancer metastasis is supported by 
the work of others who report that the VEGF-C/FLT-4 
axis promotes lung cancer cell migration and invasion 
[31]. Taken together, our findings implicate FLT4 in the 
regulation of CRC progression to a metastatic phenotype. 
It will be important for future studies to investigate the 
specific mechanism by which FLT4 acts to stimulate 
metastasis. Considering that FLT4 is a protein kinase, it 
raises the notion that a FLT4 specific kinase inhibitor may 
have significant anti-metastatic potential in CRC. In this 
regard, we want to highlight that although genistein is a 
known protein kinase inhibitor, it in fact decreased FLT4 
expression at the transcript level, resulting in decreased 
protein expression. Therefore, it is unlikely that genistein-
mediated inhibition of FLT4 kinase activity is relevant. 
Of interest, genistein decreased tumor-associated 
angiogenesis. There are several potential mechanisms 
that may be responsible for this finding. A likely one 
involves a direct extension of genistein’s anti-motility 
action. In particular, it may be inhibiting endothelial cell 
movement. This notion is further supported by the fact 
that genistein decreases FLT4 expression. Other potential 
mechanisms include modulation of microenvironmental 
cytokines, altering epithelial to mesenchymal cell 
transition, as well as others. While our findings were the 
first to demonstrate that genistein inhibited angiogenesis 
in CRC, it has previously been shown to do so in other 
cancer types, including bladder and hepatocellular 
carcinoma [32, 33]. Importantly, our identification of 
genistein-mediated suppression of FLT4 serves to provide 
a mechanistic explanation for its antiangiogenic action 
across several different tumor types. The process of neo-
angiogenesis has been recognized as a vital factor for 
sustaining tumor growth [34]. Our finding that genistein 
effectively suppressed formation of neo-angiogenesis 
has significant implications for the therapeutic use of 
genistein in humans. Anti-angiogenesis drugs, such as 
bevacizumab (anti-VEGF monoclonal antibody), have 
already been successfully approved for clinically treating 
many malignant tumors, including CRC. Nevertheless, 
the side effects associated with bevacizumab is a real 
concern clinically [35, 36]. Thus, the identification of 
novel antiangiogenic agents with less side effects, such 
as genistein, is urgently needed, and should be further 
pursued in this regard in future studies. 
Altogether, in this study, we demonstrate for the 
first time that genistein is able to selectively inhibit 
human CRC cell motility and metastasis. We also 
demonstrate that genistein exerts such inhibitory effects at 
concentrations that approximate those attained with dietary 
intake. As such, our findings provide a solid mechanistic 
rational for epidemiologic studies which associate soy 
consumption with decreased metastasis. We demonstrate 
that genistein suppresses MMP2 and FLT4, coincident 
with inhibiting cell motility and metastasis. Suppression 
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of FLT4 is accompanied by inhibition of primary tumor 
neo-angiogenesis. Our findings provide a strong rationale 
for pursuing the clinical application of genistein to inhibit 
CRC metastasis. Moreover, based on our results, MMP2, 
FLT4 and CD34 could be used as biomarkers to monitor 
genistein efficacy in clinic.
METHODS 
Cells
HCT116, SW620 and HT 29 colon cancer cell lines 
were purchased from The Cell Bank of Type Culture 
Collection of Chinese Academy of Sciences (Shanghai, 
China). All cells were cultured in DMEM supplemented 
with 10% fetal bovine serum (FBS). HCT 116-LUC cells 
(stable luciferase expression) were used for orthotopic 
transplantation, and were established by lentivirus 
infection, followed by puromycin selection. 
Cell proliferation assay
The CCK8 assay kit (Beyotime Institute of 
Biotechnology, Shanghai, China) was used to determine 
cell viability after genistein treatment. Briefly, cells were 
seeded in 96-well plate (1000 cells/well) overnight before 
complete medium containing different concentrations (0, 
10, 25, and 50 µmol/L) of genistein was added. Then the 
cells were cultured for up to 5 days. At the end of each 
day, cell viability was measured by adding CCK8 agent 
at a 10 µL/100µL medium ratio. Cells were incubated 
for 2 hr before recording absorbance at 450nm using a 
Varioskan™ Flash Multimode Reader (Thermo Fisher 
Scientific, MA, US). 
Colony formation assay
The procedures were performed as previously 
described by us [37]. Briefly, cells were pretreated with 
genistein or DMSO at the indicated dose for 24 hr before 
seeding on 6-well plate at a density of 1000 cells per well. 
After 10 days culture, the colonies were visualized by 
0.3% crystal violet staining for 15 minutes. Excess crystal 
violet was removed by rinsing the plate with PBS. The 
visible colonies were counted and the colony formation 
rate of each group was calculated with the control group 
set as 100%. 
Transwell assays
Transwell cell invasion and cell migration assays 
were used to evaluate both cell migration and invasion, 
as previously described by us [38]. Briefly, for invasion 
assays, 50,000 cells were pretreated with 10 μmol/L 
genistein or DMSO for one day before seeding in media 
without FBS into the upper chamber of each transwell, 
which was precoated with Matrigel. Media with 20% 
FBS was placed in the lower chamber and served as 
chemoattractant. Cells were allowed to invade for 24 hr 
with/without genistein treatment. After that, noninvasive 
cells on the upper surface of the membrane were removed 
by a cotton swab and cells on the lower surface of the 
membrane were fixed and stained with crystal violet. 
Invasive cells attached to the lower surface of the filter 
were visualized and photographed at 200× magnification 
using an Olymus BX51 microscope. Photographs of 3 
random fields from 3 replicate wells were recorded, and 
the number of cells was counted. For migration assay, all 
procedures were the same as in invasion assays except 
that 25,000 cells were seeded in each chamber and there 
was no Matrigel coated on the membrane of the transwell 
chamber. 
Wound healing assay
Cells were pretreated with 10 μmol/L genistein 
or DMSO one day before assay. Then, the confluent 
monolayer of cells was wounded gently by scratching 
with a 200-μL tip along the diameter of the well followed 
by PBS rinsing to remove debris. Fresh media, containing 
either genistein or DMSO, were then added. For each 
well, at least 3 pictures were taken with a microscope at 
a magnification of 100× at 3 time points (0, 24, and 48 
hrs) after scratching. The degree of wound healing was 
represented by the percentage of the non-covered wound 
area.
Single cell migration assay
As described previously with modification [39], 
cells in log phase were seeded in 96 well plates (5000 
cells/well) and incubated at 37°C to allow adhesion. 
After treating with 10 μmol/L genistein or DMSO for 
one day, cells were rinsed with serum free medium 
twice and stained with Hoechst 33342 for 15min at room 
temperature (RT). After rinsing, cells were imaged every 
45 min over a 12-hr-period using Cellomics ArrayScan® 
VTI HCS Reader (Thermo Fisher Scientific), with an 
additional incubator to maintain and image cells at 37°C. 
Specifically, the instrument randomly selected 49 evenly 
distributed fields in each well and automatically calculated 
the average migration distance of each cell. Every group 
contained 5 separate wells, i.e., N=5 replicates. 
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Orthotopic murine model of colorectal cancer 
metastasis
All the procedures involving animals were reviewed 
and protocols were approved by Xijing Hospital Animal 
Care and Use Committee. Six-to-eight week old, athymic, 
Balb/c mice were obtained from Vital River Laboratories 
(Beijing, China). To obtain subcutaneous tumor used for 
tissue transplantation, 3×106 HCT116-LUC cells were 
subcutaneously injected on each flank and allowed to 
form tumors. Two weeks after injection, subcutaneous 
tumors were isolated, cut into 2 mm pieces and kept 
briefly on ice until orthotopic implantation. For orthotopic 
transplantation, mice were anesthetized with pentobarbital 
before sterilizing. A 2-cm left abdominal flank incision 
was made and the cecum was isolated and fixed. A partial 
thickness cut in the cecal wall was made by fine needle, 
and a tumor piece was sutured into the incision. After 
re-inserting the cecum, the abdomen was closed with 
single layer suture [40]. Mice were randomly separated 
into three groups including, vehicle control (sesame 
oil), high-dose genistein (75 mg/kg/d) and low dose 
genistein (25 mg/kg/d). Three days after surgery, mice 
were weighted, and therapy begun and was administered 
daily, 5 days per week (Monday through Friday), for 5 
weeks. Throughout the experiment, mice were weighed 
weekly. After 5 weeks treatment, mice were injected 
intraperitoneally with D-Luciferin (Caliper Life Sciences, 
Hopkinton, MA, US), allowed to move about freely for 
3 minutes to promote absorption of substrate, were then 
anesthetized by isoflourane and underwent whole body 
imaging using the IVIS imaging system (Caliper Life 
Sciences, Hopkinton, MA, US). As the strong signals from 
the orthotopic tumor masked the much weaker metastatic 
signals, mice were then immediately necropsied, lung and 
liver harvested as whole organs, and their bioluminescence 
signals separately captured by IVIS imaging. Organs, and 
tumor tissues, were fixed in formalin, paraffin embedded, 
sectioned and stained with hematoxylin-and-eosin (H&E), 
and used for immunohistochemical analysis, as indicated. 
The weight of orthotopic tumor was measured, and its 
volume was calculated as 0.52× (width) 2× (length) with 
measures taken in two perpendicular dimensions, as 
previously described [21]. 
Immunohistochemical staining
All procedures were performed as previously 
described by us [21, 38, 41]. Briefly, formalin-fixed 
paraffin-embedded tissues were prepared in 4-μm sections. 
After performing dewaxing, rehydration, blocking 
endogenous peroxidase activity and antigen retrieval steps, 
sections were blocked with 10% normal goat serum at RT 
for 15 min and incubated with primary antibodies against 
MMP2, FLT4, Ki67 and CD34 (Abcam, Cambridge, 
MA, US) at 4°C overnight. Corresponding secondary 
antibodies, conjugated to HorseRadish Peroxidase 
(DAKO, Carpinteria, CA), were incubated at RT for 
30 min. Staining achieved with a DAB kit (Zhongshan 
Golden Bridge Biotechnology Company, Beijing, China), 
per manufacturer’s instructions. Microvessel density 
was determined on CD34 stained slides by counting 
five representative fields in each specimen under 200X 
magnification, as described [42]. Ki67 expression was 
determined as the percentage of positive cells in the 
representative areas examined in each specimen, as 
described by us [21]. The expression level of MMP2 
and FLT4 was calculated by considering the ratio and 
intensity of staining [31]. The ratio score was determined 
as follows: 1 for <25%, 2 for 26-50%, 3 for 51-75%, 4 for 
>75%. And the intensity score was determined as follows: 
1 for weak staining, 2 for moderate staining and 3 for a 
high level of staining. A final composite score ranging 
from 0-12 was calculated by multiplying the ratio score to 
the intensity score. The tissue array of human colon cancer 
and normal colon tissue was purchased from Xi’an Alena 
Biotechnology Company. Tissue arrays were constructed 
from tissue that had already been collected from patients 
undergoing standard-of-care treatment. Further, all 
tissue was de-identified, and no links back to the patient 
are available, nor will be attempted. Also, clinical data 
associated with each patient was provided by Alena 
Biotechnology. Here too, no patient identifier information 
is provided, all data has been de-identified, and no links 
back to patients are available, nor attempted. For FLT4 
staining in the tissue array, the final result was recorded 
as negative staining=0 (score 0~2), weak staining=1 
(score 3~5), moderate staining=2 (score 6~8) and strong 
staining=3 (score 9~12). All tissue was scored by a single 
person, and in a blinded fashion.
PCR array
Human Tumor Metastasis PCR Array (APHS-
028A; Super Array Inc.) provided by Kangcheng Gene 
Chip Company (Shanghai, China) was used. Total RNA 
was extracted from genistein treated HCT116 cells or 
DMSO treated control cells using TRIZOL® reagent 
(Invitrogen, Carlsbad, CA, US), followed by synthesis 
of cDNA using SuperScript. III Reverse Transcriptase, 
10mM dNTPs Mix, oligo (dT) 
18
 (Invitrogen) and 
RNase Inhibitor (Epicentre, Madison, WI, US), all per 
manufacturer’s protocol. The mixture of cDNA template 
and a 2×Super Array PCR master mix was added to 
the wells of the PCR Array plate (384-well) containing 
the gene-specific primer sets before real-time PCR was 
performed. The PCR cycling conditions were as follows: 
40 cycles of 95°C for 15 s, 60°C for 1min, and 72°C for 
30s. Five housekeeping genes (ACTB/NM_001101, B2M/
NM_004048, GAPDH/NM_002046, HPRT1/NM_000194 
and RPLP0/NM_001002) were used as internal controls. 
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The ΔCt value of each metastasis-related gene in each 
group was calculated. The differential expression of each 
gene was measured according to the comparative Ct 
method (ΔΔCt) [43], and the fold-change in difference 
between the genistein treated and DMSO treated control 
groups were compared. A fold-change greater than 2 was 
regarded as up-regulation, and a fold-change less than 0.5 
as down-regulation.
RNA extraction and qRT-PCR 
Total RNA from the colon cancer cells was 
extracted using TRIZOL® reagent (Invitrogen) 
according to manufacturer’s instructions, and 500 ng 
RNA of each sample was subjected to cDNA synthesis 
using TaKaRa PrimeScript RT reagent kit (TaKaRa 
Biotechnology, Dalian, China). A Roche Light Cycler 
480 PCR machine and SYBR®Premix Ex Taq™ Green 
I (TaKaRa) were used for the real-time PCR. The PCR 
program consisted of 40 cycles of the following steps: 
95°C for 5s and 60°C for 30s. The 18S mRNA was set 
as the internal control and the final expression level of 
each gene was normalized to the control group. Primer 
sequences used in real-time PCR were listed as follows: 
FLT4 forward: GCCATGTACAAGTGTGTGGTCTC, 
FLT4 reverse: ACTTGTAGCTGTCGGCTTGG; MMP2 
forward: CTCATCGCAGATGCCTGGAA, MMP2 
reverse: TTCAGGTAATAGGCACCCTTGAAGA; 18S 
forward: CGGCTACCACATCCAAGGAA, 18S reverse: 
GCTGGAATTACCGCGGCT.
Western blotting 
Protein isolation was performed as described by us 
[25]. Briefly, protein samples were prepared using RIPA 
lysis buffer (25 mmol/L Tris–HCl, pH7.5, 150 mmol/L 
NaCl, 1 mmol/L EDTA, 1% TritonX-100) containing 
protease inhibitor cocktail tablet (Roche Applied 
Science, Mannheim Germany). Proteins were separated 
by 12% Sodium dodecyl sulfate–poly-acrylamide gel 
electrophoresis and were transferred to a nitrocellulose 
membrane. After blocking with Tris-buffered saline 
containing 5% non-fat milk powder and 0.1% Tween-20 
for 1 hr at RT, the membrane was incubated with anti-
FLT4 (Cell Signaling Technology, Danvers, MA, US), 
anti-MMP2 ((Santa Cruz Biotechnology, Delaware, CA, 
USA) or anti-actin (Sigma-Aldrich, St. Louis, MO, US) 
at 4°C overnight. Goat anti-mouse secondary antibody 
(Boster, Wuhan, Hubei, China) was used to incubate the 
membrane for 1h at RT and enhanced chemiluminescence 
was then used to visualize protein bands in BIO-RAD 
ChemiDoc XRS Imaging system. 
Statistical analysis
Results were presented as the mean ± SEM 
and analyzed by two-sided Student’s t test or one-
way ANOVA for continuous variables, as indicated. 
The bioluminescence values reflecting liver and lung 
metastasis were transformed to logarithm with base 
10 before subjecting to statistical analysis. Student-
Newman-Keuls (SNK) or Games-Howell approach was 
used to perform two-group comparison after one-way 
ANOVA depending on the homogeneity of variances. 
To evaluate the association between tumor weight and 
metastatic burden, the Spearman correlation coefficient 
was used. The relation between FLT4 expression and 
clinicopathological parameters was analyzed by Pearson 
Chi-square test. The overall survival was calculated 
using Kaplan-Meier method. SPSS 19.0 software (SPSS 
Inc., Chicago, IL, US) was used for statistical analysis. 
Statistical significance was considered present for P-values 
less than 0.05.
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